

Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')

Omega Diagnostics court summons regarding alleged historical offences

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, has received a summons for its subsidiary Omega Diagnostics in relation to an alleged historical breach of HSE regulations. The alleged offences relate to Omega South West, a company previously owned by Omega Diagnostics Limited and sold in 2018.

The alleged historical breach occurred in 2018 under legislation appertaining to the possession and use of biological agents at a small facility being used by Omega South West for its trading activities during its existence. The facility in question was sold in 2018 and in the same year Omega South West ceased all trading activities. This entity has not formed any part of the Company's ongoing operations or business model and there are currently no employees within the Company who had any dealings or involvement with Omega South West.

The Company has received a summons with a first hearing scheduled for the 18th March 2025. The Company is discussing the matter with its legal advisers and determining the best course of action for all stakeholders.

The Company will make further announcements as appropriate.

Contacts:

Cambridge Nutritional Sciences plc
Carolyn Rand, Non-Executive Chair
James Cooper, Interim Chief Executive

www.cnsplc.com

Cavendish Capital Markets Limited
Geoff Nash / Edward Whiley (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

Tel: 020 7220 0500

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

STRUARNRVUUAUAR